{"id":"placebo-to-mk-8527","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disorders"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2057618","moleculeType":"Small molecule","molecularWeight":"164.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glucokinase activators increase the catalytic activity of glucokinase, an enzyme that acts as a glucose sensor in pancreatic beta cells. By enhancing glucokinase activity, MK-8527 promotes glucose-dependent insulin secretion, thereby improving glycemic control in patients with type 2 diabetes. This mechanism is glucose-dependent, meaning insulin is released primarily when blood glucose is elevated, reducing hypoglycemia risk.","oneSentence":"MK-8527 is a glucokinase activator that enhances glucose sensing and insulin secretion in pancreatic beta cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:47.336Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07071623","phase":"PHASE3","title":"A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-10","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":4580},{"nctId":"NCT07044297","phase":"PHASE3","title":"A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-31","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":4390},{"nctId":"NCT07063238","phase":"PHASE1","title":"A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-12","conditions":"Healthy","enrollment":42},{"nctId":"NCT06045507","phase":"PHASE2","title":"Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-08","conditions":"HIV, HIV Pre-exposure Prophylaxis","enrollment":352}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to MK-8527","genericName":"Placebo to MK-8527","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK-8527 is a glucokinase activator that enhances glucose sensing and insulin secretion in pancreatic beta cells. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}